Literature DB >> 14599408

[A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir].

Ramón Teira1, María M Cámara, Antonio Escobar, Pepa Muñoz, Josefina López de Munain, Juan M Santamaría.   

Abstract

BACKGROUND AND
OBJECTIVE: HIV protease inhibitors (PI) were licensed without a direct evidence of their relative efficacy. PATIENTS AND
METHOD: 137 patients attending our clinics between November 1997 and March 1998, to whom treatment with a PI was recommended, were randomized to receive indinavir (IDV), saquinavir (SQV) or ritonavir (RTV). Main outcome variables were one-year mean changes in HIV-RNA plasma concentrations and CD4 cells counts and proportion of patients with HIV viral load below level of detection.
RESULTS: Mean HIV viral load reductions were 0.95 for SQV, 0.72 for IDV and 0.65 for RTV (p = 0.44), equaling losses and changes to failures. In a standard intent-to-treat analysis, mean changes in viral load were 1.16, 1.01 and 1.50 (p = 0.21), respectively. The proportion of patients with undetectable viral load was 50%, with no differences between treatment arms.
CONCLUSIONS: No differences were observed in the effectiveness of SQV, IDV and RTV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14599408     DOI: 10.1016/s0025-7753(03)74009-3

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  1 in total

1.  The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility.

Authors:  Susan M Watanabe; Viviana Simon; Natasha D Durham; Brittney R Kemp; Satoshi Machihara; Kimdar Sherefa Kemal; Binshan Shi; Brian Foley; Hongru Li; Benjamin K Chen; Barbara Weiser; Harold Burger; Kathryn Anastos; Chaoping Chen; Carol A Carter
Journal:  Retrovirology       Date:  2016-09-06       Impact factor: 4.602

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.